HealthQuill AstraZeneca
AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.
Drugs Health Pharma

AstraZeneca completes $2.4 billion acquisition of Fusion Pharma

AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.

Read More
AstraZeneca, Daiichi’s breast cancer drug trial results show improvement in progression-free survival
Drugs Health Pharma

AstraZeneca, Daiichi’s breast cancer drug trials show rise in survival

HQ Team June 3, 2024: An antibody-drug conjugate, jointly being developed by AstraZeneca and Daiichi Sankyo, has been shown in end-stage clinical trials.

Read More
The US drug regulator has approved Amen’s biosimilar, Bkemv, to treat rare blood disorders, according to a statement from the Food and Drug Administration.
Drugs Health Pharma

US drug regulator clears Amgen’s biosimilar to treat rare blood disorder

The US drug regulator has approved Amen’s biosimilar, Bkemv,  to treat rare blood disorders, according to a statement from the Food and Drug.

Read More
AstraZeneca plans to build a $1.5 billion facility to make antibody-drug conjugates in Singapore, the company announced in a statement.
Drugs Health Pharma

AstraZeneca plans to build $1.5 billion drug making facility in Singapore 

HQ Team May 20, 2024: AstraZeneca plans to build a $1.5 billion facility to make antibody-drug conjugates in Singapore, the company announced in.

Read More
Pfizer and AstraZeneca will invest about $1 billion separately in France to set up and expand facilities, Finance Minister Bruno Le Maire said, according to a publicly-funded television network, France 24.
Drugs Health Pharma

Pfizer, AstraZeneca to invest close to $1 billion in France to expand

HQ Team May 13, 2024: Pfizer and AstraZeneca will invest about $1 billion separately in France to set up and expand facilities, Finance.

Read More
Anglo-Swedish drugmaker, AstraZeneca will acquire clinical-stage Fusion Pharmaceuticals for $2 billion in cash to get access to the latter’s radioconjugates to treat cancer.
Drugs Health Pharma

AstraZeneca to acquire Fusion Pharmaceuticals for $2 billion in cash

HQ Team March 20, 2024: Anglo-Swedish drugmaker, AstraZeneca will acquire clinical-stage Fusion Pharmaceuticals for $2 billion in cash to get access to the.

Read More
The USFDA has cleared AstraZeneca’s lung cancer drug Tagrisso with chemotherapy for treatment in adult patients.
Drugs Health Pharma

AstraZeneca’s non-small lung cancer therapy gets FDA clearance

HQ Team February 17, 2024: The USFDA has cleared AstraZeneca’s Tagrisso with chemotherapy for treatment in adult patients with non-small cell lung cancer..

Read More
Anglo-Swedish AstraZeneca Inc., and US-based Ionis Pharmaceuticals, announced the FDA has granted its nod for Wainua drug to treat nervous system impairment.
Drugs Health Pharma

USFDA clears AstraZeneca-Ionis’ drug for nervous system impairment

HQ Team December 22, 2023: Anglo-Swedish AstraZeneca Inc., and US-based Ionis Pharmaceuticals, announced the FDA has granted its nod for Wainua drug to.

Read More
The University of Cambridge announced a partnership with AstraZeneca and the Medical Research Council to set up a functional genomics laboratory at the Milner Therapeutics Institute
Drugs Health Pharma

Cambridge Univ, AstraZeneca, MRC to set up genomics laboratory

HQ Team November 29, 2023: The University of Cambridge announced a partnership with AstraZeneca and the Medical Research Council to set up a functional genomics laboratory.

Read More
AstraZeneca signed a $245 million deal with a French clinical-stage biotechnology firm, Cellectis, to speed up therapeutics in oncology, immunology and rare diseases.
Drugs Health Pharma

AstraZeneca inks $245 million deal with Cellectis for rare diseases

HQ Team November 1, 2023: AstraZeneca signed a $245 million deal with a French clinical-stage biotechnology firm, Cellectis, to speed up therapeutics in.

Read More